U.S. markets closed

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
121.74+6.67 (+5.80%)
Al cierre: 04:00PM EST
121.50 -0.24 (-0.20%)
Fuera de horario: 08:00PM EST

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo9,500

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Kevin Ronald SayerExecutive Chairman, CEO & President2.22MN/D1958
Mr. Jereme M. SylvainExecutive VP, CFO & Chief Accounting Officer841.14kN/D1980
Mr. Jacob Steven LeachExecutive VP & COO994.13kN/D1978
Mr. Girish NaganathanExecutive VP & CTO423.92kN/D1977
Mr. Michael Jon BrownExecutive VP & Chief Legal Officer954.46kN/D1970
Mr. Shelly Ramasamy SelvarajSenior VP & Chief Information OfficerN/DN/D1959
Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsN/DN/DN/D
Mr. Matthew DolanExecutive Vice President of Strategy, Corporate Development & Dexcom LabsN/DN/D1981
Ms. Leverne MarshExecutive Vice President of MarketingN/DN/DN/D
Ms. Sadie M. SternExecutive VP & Chief Human Resources OfficerN/DN/D1975
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de DexCom, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 1; Junta: 9; Derechos del accionista: 6; Compensación: 2.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.